• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

8
2
2
2

COUNTRY

2

CATEGORIES

  • 5
  • 4
  • 2
  • 1
  • 1

PRICE

8
8
9
13

PUBLISHED

0
2
4
13

PRODUCT TYPE

7
4
2

Search "Jazz Pharmaceuticals, Inc.-Deals & Alliances Report" returned 13 results.

Pharma and Biotech M&A Trends 2009-2014 [old name Merger & Acquisition Terms and Agreements] Pharma and Biotech M&A Trends 2009-2014 [old name Merger & Acquisition Terms and Agreements] - Product Thumbnail Image

Pharma and Biotech M&A Trends 2009-2014 [old name Merger & Acquisition Terms and Agreements]

The Pharma and Biotech M&A Trends 2009-2014 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma...

July 2014
FROM
Gene Therapy Partnering Terms and Agreements (3rd Edition) Gene Therapy Partnering Terms and Agreements (3rd Edition) - Product Thumbnail Image

Gene Therapy Partnering Terms and Agreements (3rd Edition)

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

December 2014
FROM

Cortex Pharmaceuticals, Inc. (CORX) - Financial and Strategic SWOT Analysis Review

Cortex Pharmaceuticals, Inc. (CORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

September 2013
FROM
Orphan Drugs - Global Strategic Business Report Orphan Drugs - Global Strategic Business Report - Product Thumbnail Image

Orphan Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts...

April 2015
FROM

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

May 2015
FROM
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - H2 2011 Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - H2 2011 - Product Thumbnail Image

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - H2 2011

Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Valeant Pharmaceuticals International, Inc. - Product Pipeline...

November 2011
FROM
Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review

Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review Summary Par Pharmaceutical Companies, Inc. (Par Pharmaceutical) is a publicly traded pharmaceutical company....

March 2012
FROM

Prescription Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors,...

July 2009
FROM
Valeant Pharmaceuticals International - Product Pipeline Review - Q4 2010 Valeant Pharmaceuticals International - Product Pipeline Review - Q4 2010 - Product Thumbnail Image

Valeant Pharmaceuticals International - Product Pipeline Review - Q4 2010

Valeant Pharmaceuticals International – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Valeant Pharmaceuticals International - Product Pipeline Review -...

December 2010
FROM
Industry Report Card: The Outlook For U.S. For-Profit Health Care Companies Is Stable, As They Face Challenging Industry Changes In 2013 May 13 Industry Report Card: The Outlook For U.S. For-Profit Health Care Companies Is Stable, As They Face Challenging Industry Changes In 2013 May 13 - Product Thumbnail Image

Industry Report Card: The Outlook For U.S. For-Profit Health Care Companies Is Stable, As They Face Challenging Industry Changes In 2013 May 13

Abstract Standard & Poor's Ratings Services expects its ratings on the U.S. for-profit health care companies it rates to remain broadly stable in 2013, with a modest negative bias, primarily in the...

May 2013
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2012 Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2012 - Product Thumbnail Image

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2012

Valeant Pharmaceuticals International, Inc. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Valeant Pharmaceuticals International, Inc. - Product Pipeline...

May 2012
FROM
North American Corporate Rating Scores By Industry Sector As Of March 5, 2015 May 15 North American Corporate Rating Scores By Industry Sector As Of March 5, 2015 May 15 - Product Thumbnail Image

North American Corporate Rating Scores By Industry Sector As Of March 5, 2015 May 15

Abstract Standard & Poor's Ratings Services is updating the rating component scores for its public corporate credit ratings in North America. This article follows a similar report published on Feb....

May 2015

Soft Drinks - Global Strategic Business Report

This report analyzes the worldwide markets for Soft Drinks in Millions of Liters and US$ Million The major product segments analyzed are Carbonates, and Non-Carbonates The sub product segments analyzed...

February 2006
FROM
Loading Indicator

Our Clients

Glanbia Plc. Unilever N.V. Microsoft Corporation Duke University A.T. Kearney PepsiCo Inc. Boston Consulting Group